Scarica l'app Stockscreener
60.62
3.55%
-2.23
Dopo l'orario di chiusura:
60.62
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$62.85
Aprire:
$62.37
Volume 24 ore:
761.02K
Relative Volume:
0.91
Capitalizzazione di mercato:
$2.82B
Reddito:
$1.35B
Utile/perdita netta:
$163.34M
Rapporto P/E:
18.50
EPS:
3.2763
Flusso di cassa netto:
$189.17M
1 W Prestazione:
-6.26%
1M Prestazione:
+5.43%
6M Prestazione:
+13.35%
1 anno Prestazione:
-11.24%
Intervallo 1D:
$59.83
$63.47
Intervallo di 1 settimana:
$59.83
$65.10
Portata 52W:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Nome
Haemonetics Corp
Settore
Industria
Telefono
(781) 848-7100
Indirizzo
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
60.62 | 2.92B | 1.35B | 163.34M | 189.17M | 3.2763 |
|
ABT
Abbott Laboratories
|
110.25 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
345.78 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
88.97 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.63 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.09 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | Needham | Buy → Hold |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Reiterato | Barrington Research | Outperform |
| 2025-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-06-26 | Iniziato | Robert W. Baird | Outperform |
| 2025-02-07 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Iniziato | JP Morgan | Overweight |
| 2024-11-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Iniziato | CL King | Buy |
| 2024-09-11 | Iniziato | BofA Securities | Neutral |
| 2024-09-10 | Iniziato | BTIG Research | Buy |
| 2024-06-12 | Aggiornamento | Needham | Hold → Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-01-27 | Downgrade | Needham | Buy → Hold |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-17 | Ripresa | Raymond James | Outperform |
| 2021-06-17 | Iniziato | Citigroup | Buy |
| 2021-05-14 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Iniziato | Needham | Buy |
| 2019-08-07 | Reiterato | Barrington Research | Outperform |
| 2019-05-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Reiterato | Barrington Research | Outperform |
| 2018-08-09 | Reiterato | Barrington Research | Outperform |
| 2018-02-07 | Reiterato | Barrington Research | Outperform |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Reiterato | Barrington Research | Outperform |
| 2017-08-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Reiterato | The Benchmark Company | Hold |
| 2016-09-20 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Downgrade | Sidoti | Buy → Neutral |
| 2016-08-02 | Reiterato | Jefferies | Buy |
| 2016-08-02 | Reiterato | The Benchmark Company | Hold |
Mostra tutto
Haemonetics Corp Borsa (HAE) Ultime notizie
Citigroup Maintains Neutral Rating on Haemonetics (HAE), Lowers Price Target | HAE Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics price target lowered to $70 from $75 at Citi - TipRanks
Haemonetics launches recruitment drive to expand clinical support roles - Traders Union
Assessing Haemonetics (HAE) Valuation After Recent Share Price Pullback - Yahoo Finance
A Look Back at Medical Devices & SuppliesSpecialty Stocks’ Q4 Earnings: Haemonetics (NYSE:HAE) Vs The Rest Of The Pack - Yahoo Finance
A Review of Q4 Earnings for Medical Devices & Supplies Specialty Stocks: Comparing Haemonetics (NYSE:HAE) to Its Competitors - Bitget
Haemonetics Wins FDA Nod For Persona PLUS Plasma Growth Opportunity - simplywall.st
Haemonetics Corporation $HAE Shares Sold by Fisher Asset Management LLC - MarketBeat
Haemonetics Repays $300 Million Convertible Senior Notes Due 2026 - marketscreener.com
William Blair Investment Management LLC Buys 57,332 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp repays outstanding 0.00% convertible senior notesSEC filing - marketscreener.com
Haemonetics repays $300 million convertible notes at maturity By Investing.com - Investing.com Canada
Haemonetics repays $300 million convertible notes at maturity - Investing.com
Haemonetics Retires 2026 Convertible Notes, Simplifies Capital Structure - TipRanks
Haemonetics repays $300M 0.00% convertible notes due 2026 in cash - TradingView
Assessing Haemonetics (HAE) Valuation After FDA Clearance Of NexSys PCS Persona PLUS System - simplywall.st
3 Reasons HAE is Risky and 1 Stock to Buy Instead - Finviz
Haemonetics at Raymond James: Strategic Growth and Challenges - Investing.com Nigeria
Haemonetics at Raymond James: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Here's Why Haemonetics (HAE) is a Strong Value Stock - Yahoo Finance
Royce & Associates LP Sells 569,815 Shares of Haemonetics Corporation $HAE - MarketBeat
Vanguard Group Inc. Reduces Stock Position in Haemonetics Corporation $HAE - MarketBeat
Kestrel Investment Management Corp Purchases New Shares in Haemonetics Corporation $HAE - MarketBeat
Ameritas Investment Partners Inc. Has $636,000 Holdings in Haemonetics Corporation $HAE - MarketBeat
Is Haemonetics (HAE) Offering A Compelling Entry Point After Prolonged Share Price Weakness - simplywall.st
Haemonetics Corporation $HAE Stake Lessened by Citigroup Inc. - MarketBeat
Q1 EPS Estimates for Haemonetics Decreased by Zacks Research - MarketBeat
Fox Run Management L.L.C. Takes $1.36 Million Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Completes Hemerus Medical Acquisition - Yahoo
Zacks Research Forecasts Increased Earnings for Haemonetics - MarketBeat
Therapeutic Apheresis Market to Reach US$ 6,009.58 Million - openPR.com
Haemonetics (HAE) Is Up 5.3% After FDA Clears NexSys PCS With Persona PLUS Technology - simplywall.st
Haemonetics receives FDA clearance for plasma collection system - Investing.com
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology - PR Newswire
Clark Estates Inc. NY Takes $2.24 Million Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics receives FDA clearance for plasma collection system By Investing.com - Investing.com Canada
Haemonetics Stock After Earnings: Quiet Breakout or Value Trap? - AD HOC NEWS
Isthmus Partners LLC Acquires 16,505 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference - PR Newswire
Haemonetics Corporation (NYSE:HAE) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Haemonetics Corporation $HAE Stock Holdings Lessened by Heartland Advisors Inc. - MarketBeat
ABN Amro Investment Solutions Buys Shares of 200,000 Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (HAE) Q3 Performance Prompts Baird Model Update, Price Target Falls to $81 - Finviz
Growth Recap: Will Haemonetics Corporation outperform its industry peersJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
Assessing Haemonetics (HAE) Valuation After Recent Share Price Weakness - Yahoo Finance
A Look At Haemonetics (HAE) Valuation After Recent Share Price Weakness - simplywall.st
Strong Competitive Position Drove Haemonetics Corporation’s (HAE) Earnings Growth - Yahoo Finance
Short Interest in Haemonetics Corporation (NYSE:HAE) Decreases By 21.7% - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Principal Financial Group Inc. - MarketBeat
Haemonetics Releases 2024-2025 Corporate Responsibility Report - The Globe and Mail
Haemonetics Corp Azioni (HAE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.21%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):